LYMPHOMA

BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons


Normal development of lymphocytes


Lymphocyte proliferation and differentiation:

- B-cell Pathway (in bone marrow): [Stem Cell, Early B Precursor, Pre-B] hematogones, mature B cell, Plasma cell (terminally differentiated).
- NK/T-cell Pathway (in thymus): Stem Cell, Early Thymocytes, Common Thymocytes, Mature (peripheral/post-thymic) T-cells.

Normal Lymph Node

- Normal compartments of the lymph node:
- 1- cortex / follicles
- 2- paracortex
- 3- medullary cords
- 4- sinuses






Diagnostic Methods


- Histologic evaluation of lymphoid tissue and ancillary diagnostic studies:
- Paraffin-embedded fixed tissue for routine histology
- Immunophenotyping (by immunohistochemistry and/or flow cytometry)


Lymphoid Markers

Lymphoid markers commonly used in immunophenotypic studies:

B-cell markers: CD19, CD20, CD22, CD79a, Pax5.. T-cell markers: CD2, CD3, CD5, CD7,CD4, CD8.. Germinal center cells: CD10, Bcl-6.. Immature lymphoid cells: TdT, CD10, CD34.. Activated lymphoid cells: CD30, CD23.. NK-cells: CD56, CD57.. Hodgkin's cells: CD30, CD15, Pax5..







Diagnostic Methods, cont.

- Cytogenetic studies: Conventional Karyotype analysis, FISH analysis, SKY analysis
- Molecular analysis: Southern blot and PCR
- DNA microarray platforms: important methodology for the diagnosis and classification of hematological malignancies in the future

LYMPHOID DISORDERS

- 1- Benign (reactive) Lymphadenopathies
- 2- Malignant Lymphoproliferative Disorders/Lymphomas
- 3- Atypical Lymphoproliferative Disorders

LYMPHOMAS

- Non-Hodgkin Lymphoma (NHL): B-cell lymphomas (most common) T-cell and NK cell lymphomas
- Hodgkin Lymphoma (disease): Nodular Lymphocyte Predominance Classical Hodgkin Lymphoma

Non-Hodgkin Lymphoma

• **Definition:**

Malignant neoplastic proliferation of lymphoid cells derived from a single transformed cell (monoclonal proliferation).

• Epidemiology:

- There has been a steady increase in incidence in the United States
- More common in the developed countries
- Frequency of different types varies around the world (B- vs. NK/T-cell, Burkitt lymphoma, adult T-cell leukemia/lymphoma)

Non-Hodgkin Lymphoma

- Epidemiology, cont.:
- Individuals with immunodeficiencies/immune disorders are at higher risk :
- 1- Congenital (primary) immunodeficiency
- 2- Acquired immunodeficiencies (HIV-related, post-therapy)
- 3- Autoimmune diseases..

- Etiology:
- Infectious agents and development of malignant lymphoma:
 - * HTLV-1 infection and T-cell leukemia/lymphoma..
 - * Epstein-Barr virus (EBV) and Burkitt's lymphoma..
 - * Human herpesvirus-8 (HHV-8) in primary effusion lymphomas
 - * H. Pylori and gastric MALT lymphoma



- Etiology, cont.:
- Genetic alterations and development of lymphoma..
 - t(14;18) translocation and follicular lymphoma..
 - t(8;14) translocation and Burkitt's lymphoma..
 - t(11;14) translocation and mantle cell lymphoma..

Classification of NHLs:

* Rappaport Classification:

Based on morphology; growth pattern (diffuse vs. nodular) and cytomorphology..

* Working Formulation:

Based on morphology; divides NHLs into prognostic groups (useful to clinicians) and can be applied in the absence of immunophenotypic studies..

Non-Hodgkin Lymphoma

- Classification of NHLs, cont.:
- * Revised European American Lymphoma (REAL) Classification:

This classification system recognizes specific (real) disease entities based on immunophenotypic, cytogenetic, and molecular features, as well as conventional morphology.

WHO Classification:

- An updated version of the REAL classification..
- Expanded the principles of the REAL classification to the classification of the myeloid and histiocytic neoplasms..
- Replaced existing classifications..
- The first international consensus..

WHO Classification

 Precursor (immature) B- and T-cell Lymphoid Neoplasms (leukemia/lymphoma):

Precursor lymphblastic leukemia/lymphoma

- Mature (peripheral) B- and T-cell Lymphoid Neoplasms:
 - Mature B-cell lymphomas Mature NK/T-cell lymphomas

WHO Classification

- Immunodeficiency Associated Lymphoproliferative Disorders:
- 1. Lymphoproliferative diseases associated with primary immune disorders
- 2. Lymphomas associated with infection by HIV
- 3. Post-transplant lymphoproliferative disorders
- 4. Methotraxate-associated lymphoproliferative disorders

Non-Hodgkin Lymphoma


- Clinical manifestations of NHL:
- 1- Lymphadenopathy..
- 2- Organomegaly (infiltration of organs)..
- **3- Systemic/B symptoms** (fever, night sweats, weight loss)..


 Examples of NHL:
Diffuse Large B-cell Lymphoma (DLBCL)
Follicular Lymphoma (FL)
Burkitt Lymphoma (BL)

Non-Hodgkin Lymphoma

Diffuse Large B-cell Lymphoma


A diffuse proliferation of large neoplastic B lymphoid cells with a nuclear size equal to or exceeding normal macrophage nuclei or more than twice the size of a normal lymphocyte








Follicular Lymphoma

A neoplasm of follicle center B cells (a mixture of centrocytes/centroblasts), which has at least a partially follicular/nodular pattern of growth











Burkitt Lymphoma

A highly aggressive lymphoma often presenting at an extra-nodal site or in a leukemic phase, composed of monomorphic medium-sized B-cells with basophilic/vacuolated cytoplasm and numerous mitotic figures





- Therapy of NHL:
- **1- Chemotherapy**
- 2- Radiotherapy
- 3- Combined chemo- and radiotherapy
- 4- Immune therapy: antibodies raised against B-cell antigens (anti- CD20 antibodies)

Hodgkin Lymphoma

• **Definition:**

Lymphoid neoplasm with a minority of neoplastic lymphoid cells (*Hodgkin cells*) in a predominant inflammatory/reactive background which may mask the tumor cell population

- Epidemiology & Etiology :
- accounts approximately for 30% of all malignant lymphomas
- absolute incidence has not apparently changed
- bimodal age distribution
- EBV has been postulated to play a role in the pathogenesis of classical HL

Hodgkin Lymphoma

• WHO Classification of HL:


1- Nodular Lymphocyte


Predominance, probably will be considered or reclassified as a B-cell lymphoma in the future..

2- Classical Hodgkin Lymphoma

Nodular Lymphocyte Predominance:

- uncommon variant (6% of HL)
- characteristic nodular pattern of growth
- characteristic variant of Hodgkin cells (known as "popcorn" cells), which are CD20 positive B-cells of follicle center cell origin (CD10+, Bcl-6+)





Classical Hodgkin Lymphoma:

Nodular sclerosis (NSHL) Mixed cellularity (MCHL) Lymphocyte depletion (LDHL) Lymphocyte -rich classical Hodgkin lymphoma (LRCHL)

Classical Hodgkin Lymphoma:


- Hodgkin cells: derived from mature B-cells at the germinal center stage of differentiation
- typical Reed-Sternberg cells (binucleated cells)
- variants (mono- and multinucleated forms and lacunar cells)


Immunophenotype: CD30+, CD15+, Pax5+, and CD45 negative


Hodgkin Lymphoma


Classical Hodgkin Lymphoma: Nodular sclerosis (NSHL):


 characterized by Reed-Sternberg cells and *lacunar cells* within a polymorphic reactive background, and a characteristic *fibrosis* (bands of collagen surrounding nodules)











Classical Hodgkin Lymphoma: Mixed cellularity (MCHL):

 classical Reed-sternberg cells in a mixed, polymorphic bachground; no lacunar cells or collagen bands

Lymphocyte depletion (LDHL):

- uncommon subtype
- rich in Hodgkin's cells

- Clinical manifestations of HL:
- 1- Lymphadenopathy
- 2- Organomegaly (infiltration of organs)
- **3- Systemic/B symptoms** (fever, night sweats, weight loss)

Hodgkin's Lymphoma

- Therapy of HL:
- 1- Chemotherapy
- 2- Radiotherapy